KRAS vaccine generates immune response in pancreatic cancer trial

· Science · United States

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers and published in Nature Medicine. The findings will help researchers design a larger phase 3 trial. Pancreatic cancer is among the most aggressive and treatment-resistant tumors, and the KRAS mutations targeted here are present in the majority of cases. A vaccine approach that trains the immune system on those mutations would represent a different strategy from conventional chemotherapy. The report does not give response rates, survival data or the number of patients enrolled. Immediate interest will center on whether the immune response translates into clinical benefit in the phase 3 study, and on the wider push to develop KRAS-directed therapies.

Why it matters：Pancreatic cancer has few effective options, so a vaccine that targets its most common driver mutations would matter well beyond one trial, feeding the broader race to drug KRAS.

Key points

  • The vaccine targets mutations that drive most pancreatic cancers.
  • Results come from a randomized phase 2 trial led by Mayo Clinic and published in Nature Medicine.
  • Researchers will use the findings to design a phase 3 trial.

Sources (original reporting)

More stories from this day